TrivarX Ltd (ASX: TRI) - Share Price

- Current share price for TRI : $0.015

TrivarX Ltd (TRI) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a mental health technology company pioneering the use of objective measures to aid in early detection and screening of mental health conditions. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). The Company is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market.

TRI General Information ⁺

ASX Code	TRI
Website	N/A
Industry/Sector	Health Care Technology
Market Cap ($M)	17
TRI Share Price	$0.015
Day High	$0.015
Day Low	$0.015
Last Close	$0.015
TRI Share Price Movement	- ( No change )

Prices as at 16:40, 4 Sep 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

TrivarX Ltd (TRI) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from TrivarX Ltd (TRI) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

TrivarX Ltd (TRI) price-sensitive announcements

TRI - June 2026 Quarterly Activities Report and Appendix 4C

TrivarX Limited reported its June 2026 Quarterly Activities, highlighting significant stri

TrivarX Ltd (TRI)
28 Jul 2026 | 2:02 PM

TRI - Stabl-Im clinical trial supply milestone achieved

TrivarX Limited announced a significant milestone with the securing of investigational pro

TrivarX Ltd (TRI)
16 Jul 2026 | 9:15 AM

TRI - CRO Engaged to Advance Stabl-Im Phase 1 Trial

TrivarX Limited has announced the engagement of Beyond Drug Development, a specialist Cont

TrivarX Ltd (TRI)
22 May 2026 | 9:36 AM

TRI - March 2026 Quarterly Activities Report and Appendix 4C

TrivarX Limited, an Australian healthcare technology company, reported significant progres

TrivarX Ltd (TRI)
30 Apr 2026 | 9:38 AM

TrivarX Ltd (TRI) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
TrivarX Ltd (TRI) ORDINARY FULLY PAID	Health Care	$17	Appendix 4E - Preliminary Final Report	27 Aug 2026 1:05PM	$0.015	$0.015	fallen by 0%
TrivarX Ltd (TRI) ORDINARY FULLY PAID	Health Care	$17	June 2026 Quarterly Activities Report and Appendix 4C	28 Jul 2026 2:02PM	$0.016	$0.015	fallen by 6.25%
TrivarX Ltd (TRI) ORDINARY FULLY PAID	Health Care	$17	Stabl-Im clinical trial supply milestone achieved	16 Jul 2026 9:15AM	$0.020	$0.015	fallen by 25%
TrivarX Ltd (TRI) ORDINARY FULLY PAID	Health Care	$17	Investor Presentation - Stabl-Im program	25 Jun 2026 9:19AM	$0.022	$0.015	fallen by 31.82%
TrivarX Ltd (TRI) ORDINARY FULLY PAID	Health Care	$17	Change of Registered Office Address	26 May 2026 2:06PM	$0.028	$0.015	fallen by 46.43%
TrivarX Ltd (TRI) ORDINARY FULLY PAID	Health Care	$17	CRO Engaged to Advance Stabl-Im Phase 1 Trial	22 May 2026 9:36AM	$0.029	$0.015	fallen by 47.37%

TRI Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2026A	-$8.42	-$91.90	48,242.10%	0.00%	0.0%
2025A	-$0.94	-$0.20	-48.70%	0.00%	0.0%
2024A	-$1.24	-$0.40	-63.40%	0.00%	0.0%

TRI Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A
4DMedical Limited (4DX)	$2,064M	1.4982	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Pro Medicus Limited (PME)	$18,042M	1.3034	-0.2811	0.2395	68.0994	94.7288	76.4227	0.40%	0.54%	0.66%
TrivarX Ltd (TRI)	$17M	482.4211	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%

TRI Directors

Name	Position	Start Date
Dr Anthony (Tony) Keating	Executive Director	31 Jul 2024
Mr Christopher Ntoumenopoulos	Non-Executive Director	15 Feb 2023
Mr David Edward Trimboli	Non-Executive Director, Non-Executive Chairman	25 Aug 2022

TrivarX Ltd (TRI) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
19 Dec 2025	NTOUMENOPOULOS, Christopher	Issued	Direct Shares	6,250,000	$0.008	$50,000.000
19 Dec 2025	TRIMBOLI, David	Issued	Indirect Shares	6,250,000	$0.008	$50,000.000
19 Dec 2025	NTOUMENOPOULOS, Christopher	Issued	Indirect Shares	5,000,000	$0.008	$40,000.000

See all changes in directors' interest & trades for TrivarX Ltd (TRI) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

TRI Management

Name	Position
Danielle Meyrick	Chief Executive Officer
Kai Sun	Chief Operating Officer
Nova Taylor	Joint Company Secretary
Cameron Jones	Joint Company Secretary

TRI Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in TrivarX Ltd (TRI). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
42,502,362 (7.47%)	FIL Limited and the entities

TRI Calendar of Events

Date	Event
26 August 2027	Report (Prelim)
23 February 2027	Report (Interim)
28 September 2026	Report (Annual)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us